title: Surveillance for adverse events following immunization from 2008 to 2011 in Zhejiang Province, China.
abstract: This study summarizes passive surveillance data for adverse events following immunization (AEFI) reported to the National AEFI Surveillance System (NASS) in Zhejiang province and describes reporting trends from 2008 to 2011. AEFI reporting rates were calculated using denominator data from the Individual Immunization Information System and the Zhejiang provincial Bureau of Statistics. A total of 6,265 AEFI records were reported; the overall reporting rate was 9.2 per 100,000 doses. There were two peaks of reporting rates, which were associated mainly with the introduction of the pandemic H1N1 influenza virus vaccine (pH1N1) in 2009 and the measles-mumps vaccine (MM) campaign in 2010. The majority of the AEFI described nonserious events. Fifteen deaths were recorded, but only one was possibly related to immunization. The most frequently reported reactions were fever and injection site reaction. Vaccines distributed in Zhejiang province have proven to be generally safe. The data on AEFI surveillance provide a reference point for ongoing reporting of trends and illustrate the value of the NASS database as a surveillance tool for monitoring of AEFI.
authors.affiliation: Institute of Immunization and Prevention, Zhejiang Center for Disease Control and Prevention, Hangzhou, China. husix@163.com
authors.forename: Yu
authors.initials: Y
authors.lastname: Hu
authors.forename: Qian
authors.initials: Q
authors.lastname: Li
authors.forename: Luoya
authors.initials: L
authors.lastname: Lin
authors.forename: Enfu
authors.initials: E
authors.lastname: Chen
authors.forename: Yaping
authors.initials: Y
authors.lastname: Chen
authors.forename: Xiaohua
authors.initials: X
authors.lastname: Qi
mesh_terms: D016907:Adverse Drug Reaction Reporting Systems / Q000706:statistics & numerical data*; D000707:Anaphylaxis; D002681:China; D062665:Epidemiological Monitoring; D020275:Guillain-Barre Syndrome; D006801:Humans; D007114:Immunization / Q000009:adverse effects*; D017589:Immunization Programs; D053118:Influenza A Virus, H1N1 Subtype / Q000276:immunology; D007252:Influenza Vaccines / Q000009:adverse effects; D022542:Measles-Mumps-Rubella Vaccine / Q000009:adverse effects; D011159:Population Surveillance; D014611:Vaccination / Q000009:adverse effects*
chemical_list: D007252:Influenza Vaccines; D022542:Measles-Mumps-Rubella Vaccine